SCHEMBL20069779

SCHEMBL20069779

CN1CCC(C)(C(=O)NCC2CC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 2/20 0.44
MAPT P10636 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TSHR P16473 3/20 0.38
RET P07949 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
KCNH2 Q12809 1/20 0.36
CACNA1I Q9P0X4 1/20 0.36
EPHX1 P07099 4/20 0.35
EPHX2 P34913 4/20 0.35
NAMPT P43490 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069680 0.90 RET (0.38) CYP3A4SMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL20148017 0.85 SMN1; SMN2 (0.43) CYP3A4SMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL20158498 0.83 SMN1; SMN2 (0.43) CYP3A4SMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL20069154 0.82 RET (0.41) ALDH1A1KMT2ATSHRRETKCNH2
SCHEMBL19198339 0.79 EPHX1 (0.44) CYP3A4SMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL22172283 0.79 KMT2A (0.41) ALDH1A1KDM4EKMT2ATDP1KCNH2
SCHEMBL20205998 0.78 SMN1; SMN2 (0.40) CYP3A4SMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL20069676 0.78 TSHR (0.52) SMN1; SMN2ALDH1A1HPGDKDM4EMEN1
SCHEMBL18377462 0.78 CYP3A4 (0.42) CYP3A4SMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL20069677 0.75 CYP2C19 (0.46) SMN1; SMN2KDM4ERETHDAC3HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CYP3A4 3760/4885SMN1; SMN2 646/4885ALDH1A1 2547/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CYP3A4 3760/4885SMN1; SMN2 646/4885ALDH1A1 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.